Efficacy and Toxicity Seen With MIRV in Ovarian Cancer ...Middle East

News by : (Medscape) -
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer. Medscape Medical News

Hence then, the article about efficacy and toxicity seen with mirv in ovarian cancer was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Efficacy and Toxicity Seen With MIRV in Ovarian Cancer )

Last updated :

Also on site :

Most Viewed News
جديد الاخبار